Why Lilly And Novo Nordisk Will Keep Dominating The Market For Blockbuster GLP-1 Drugs

Despite supply shortages, the GLP-1 drugs by the two companies saw their sales surge in the first quarter of the year, and competitors are still trying to catch up.